• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Pediatr . Risk factors for severe post-COVID condition in children, adolescents, and young adults

tetano

Editor, Senior Moderator
Eur J Pediatr


. 2026 May 4;185(5):344.
doi: 10.1007/s00431-026-06995-3.
Risk factors for severe post-COVID condition in children, adolescents, and young adults

Quirin Donath[SUP] 1 [/SUP], Matthias Haegele[SUP] 1 [/SUP], Daniela Schindler[SUP] 1 2 [/SUP], Tiziana Welzhofer[SUP] 1 [/SUP], Catharina Christa[SUP] 1 [/SUP], Annika Grabbe[SUP] 1 [/SUP], Ariane Leone[SUP] 1 [/SUP], Clara Ilhan[SUP] 1 [/SUP], Carola Weidmann[SUP] 1 [/SUP], Maria Eberhartinger[SUP] 1 [/SUP], Sara Bechtold[SUP] 3 [/SUP], Nicola Bursch[SUP] 3 [/SUP], Hedwig Wolf[SUP] 1 3 [/SUP], Hannah Hieber[SUP] 1 [/SUP], Laura-Carlotta Peo[SUP] 1 [/SUP], Lara A Bucka[SUP] 1 [/SUP], Silvia Stojanov[SUP] 3 4 [/SUP], Cordula Warlitz[SUP] 1 [/SUP], Martin Alberer[SUP] 1 [/SUP], Katrin Gerrer[SUP] 1 [/SUP], Anna Hausruckinger[SUP] 1 [/SUP], Kirstin Mittelstrass[SUP] 1 [/SUP], Clemens-Martin Wendtner[SUP] 5 [/SUP], Manuela A Hoechstetter[SUP] 5 [/SUP], Armin Grübl[SUP] 1 [/SUP], Nicole Toepfner[SUP] 6 [/SUP], Rafael Pricoco[SUP] 1 [/SUP], Carmen Scheibenbogen[SUP] 7 [/SUP], Lorenz L Mihatsch[SUP] #[/SUP][SUP] 8 [/SUP], Uta Behrends[SUP] #[/SUP][SUP] 1 2 [/SUP]


Affiliations
Abstract

Post-COVID condition (PCC) in children and young people (CYP, PCCcyp) remains a significant health burden. Early identification of patients at risk for severe disease, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is crucial for timely and adequate care. This monocentric, observational registry study, performed at a tertiary pediatric hospital in Germany, included CYP aged 7-25 years with PCCcyp at diagnosis. Standardized clinical assessment tools and patient-reported outcome measures were applied, including the novel Munich Long COVID Symptom Questionnaire (MLCSQ). Severe PCC was defined by chronic symptom clusters, Fatigue Severity Scale (FSS), Total Composite Autonomic Symptom Score-31 (COMPASS-31), SF-36 composite scores, Bell Score, and confirmed ME/CFS diagnosis. Among 120 participants, severe PCCcyp was associated with a higher number of acute symptoms (OR[SUB]adj[/SUB] 1.22, P < 0.001), acute orthostatic intolerance (OR[SUB]adj[/SUB] 9.87, P = 0.002), acute trouble concentrating (OR[SUB]adj[/SUB] 11.8, P = 0.005), and female sex (OR 3.31, P = 0.031). Categorizing acute symptoms at a threshold of ≥ 12 yielded optimal model performance (AUC 0.857; sensitivity 65.6%; specificity 90.2%). ME/CFS was diagnosed in 24% of participants, all within the severe PCCcyp cluster, and was characterized by greater acute symptom complexity, more fatigue, more autonomic symptoms, and poorer function. Conclusions: The number and pattern of acute symptoms during SARS-CoV-2 infection may serve as early, specific predictors of severe PCCcyp. Patients with ≥ 12 acute symptoms should be closely monitored to enable early diagnosis of severe PCCcyp and ME/CFS. A distinct cluster of severely affected patients, frequently with ME/CFS, was identified.Trial registration: ClinicalTrials.gov: NCT05638724; Ethics approval (511/21, 2025-465-S-SB).

Keywords: Long COVID; Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); Post-COVID syndrome (PCS); Post-COVID-19 condition (PCC); Post-acute sequelae of COVID-19 (PASC); Post-exertional malaise (PEM).

 
Back
Top